These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 36313205)

  • 1. Wntless expression promotes lineage plasticity and is associated with neuroendocrine prostate cancer.
    D'Abronzo LS; Lombard AP; Ning S; Armstong CM; Leslie AR; Sharifi M; Schaaf ZA; Lou W; Gao AC
    Am J Clin Exp Urol; 2022; 10(5):299-310. PubMed ID: 36313205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Wntless promotes cellular viability and resistance to enzalutamide in castration-resistant prostate cancer cells.
    Lombard AP; Liu C; Armstrong CM; D'Abronzo LS; Lou W; Evans CP; Gao AC
    Am J Clin Exp Urol; 2019; 7(4):203-214. PubMed ID: 31511827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. WLS-Wnt signaling promotes neuroendocrine prostate cancer.
    Bland T; Wang J; Yin L; Pu T; Li J; Gao J; Lin TP; Gao AC; Wu BJ
    iScience; 2021 Jan; 24(1):101970. PubMed ID: 33437943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of neural lineage networks and ARHGEF2 in enzalutamide-resistant and neuroendocrine prostate cancer and association with patient outcomes.
    Ning S; Zhao J; Lombard AP; D'Abronzo LS; Leslie AR; Sharifi M; Lou W; Liu C; Yang JC; Evans CP; Corey E; Chen HW; Yu A; Ghosh PM; Gao AC
    Commun Med (Lond); 2022; 2():118. PubMed ID: 36159187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reprogramming hormone-sensitive prostate cancer to a lethal neuroendocrine cancer lineage by mitochondrial pyruvate carrier (MPC).
    Xu H; Liu Z; Gao D; Li P; Shen Y; Sun Y; Xu L; Song N; Wang Y; Zhan M; Gao X; Wang Z
    Mol Metab; 2022 May; 59():101466. PubMed ID: 35219875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular model for neuroendocrine prostate cancer progression.
    Chen R; Dong X; Gleave M
    BJU Int; 2018 Oct; 122(4):560-570. PubMed ID: 29569310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer.
    Liu C; Chen B; Xu P; Yang J; Nip C; Wang L; Shen Y; Ning S; Shang Y; Corey E; Gao AC; Gestwicki J; Wei Q; Liu L
    Res Sq; 2024 Mar; ():. PubMed ID: 38585965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current advances of targeting epigenetic modifications in neuroendocrine prostate cancer.
    Cheng WC; Wang HJ
    Tzu Chi Med J; 2021; 33(3):224-232. PubMed ID: 34386358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synaptophysin expression on circulating tumor cells in patients with castration resistant prostate cancer undergoing treatment with abiraterone acetate or enzalutamide.
    Pal SK; He M; Chen L; Yang L; Pillai R; Twardowski P; Hsu J; Kortylewski M; Jones JO
    Urol Oncol; 2018 Apr; 36(4):162.e1-162.e6. PubMed ID: 29289429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ZNF397 Deficiency Triggers TET2-driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer.
    Xu Y; Yang Y; Wang Z; Sjostrom M; Jiang Y; Tang Y; Cheng S; Deng S; Wang C; Gonzalez J; Johnson NA; Li X; Li X; Metang LA; Mukherji A; Xu Q; Tirado CR; Wainwright G; Yu X; Barnes S; Hofstad M; Chen Y; Zhu H; Hanker AB; Raj GV; Zhu G; He HH; Wang Z; Arteaga CL; Liang H; Feng FY; Wang Y; Wang T; Mu P
    Cancer Discov; 2024 Apr; ():. PubMed ID: 38591846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of transcription factors and chromatin modifiers in driving lineage reprogramming in treatment-induced neuroendocrine prostate cancer.
    Sreekumar A; Saini S
    Front Cell Dev Biol; 2023; 11():1075707. PubMed ID: 36711033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer.
    Liu C; Armstrong CM; Lou W; Lombard AP; Cucchiara V; Gu X; Yang JC; Nadiminty N; Pan CX; Evans CP; Gao AC
    Mol Cancer Ther; 2017 Aug; 16(8):1521-1530. PubMed ID: 28500234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular plasticity and the neuroendocrine phenotype in prostate cancer.
    Davies AH; Beltran H; Zoubeidi A
    Nat Rev Urol; 2018 May; 15(5):271-286. PubMed ID: 29460922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer.
    Berger A; Brady NJ; Bareja R; Robinson B; Conteduca V; Augello MA; Puca L; Ahmed A; Dardenne E; Lu X; Hwang I; Bagadion AM; Sboner A; Elemento O; Paik J; Yu J; Barbieri CE; Dephoure N; Beltran H; Rickman DS
    J Clin Invest; 2019 Jul; 129(9):3924-3940. PubMed ID: 31260412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and Biological Features of Neuroendocrine Prostate Cancer.
    Yamada Y; Beltran H
    Curr Oncol Rep; 2021 Jan; 23(2):15. PubMed ID: 33433737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-transcriptional Gene Regulation by MicroRNA-194 Promotes Neuroendocrine Transdifferentiation in Prostate Cancer.
    Fernandes RC; Toubia J; Townley S; Hanson AR; Dredge BK; Pillman KA; Bert AG; Winter JM; Iggo R; Das R; Obinata D; ; Sandhu S; Risbridger GP; Taylor RA; Lawrence MG; Butler LM; Zoubeidi A; Gregory PA; Tilley WD; Hickey TE; Goodall GJ; Selth LA
    Cell Rep; 2021 Jan; 34(1):108585. PubMed ID: 33406413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding and targeting prostate cancer cell heterogeneity and plasticity.
    Tang DG
    Semin Cancer Biol; 2022 Jul; 82():68-93. PubMed ID: 34844845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms and Approaches for Overcoming Enzalutamide Resistance in Prostate Cancer.
    Vander Ark A; Cao J; Li X
    Front Oncol; 2018; 8():180. PubMed ID: 29911070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ZNF397 Loss Triggers TET2-driven Epigenetic Rewiring, Lineage Plasticity, and AR-targeted Therapy Resistance in AR-dependent Cancers.
    Xu Y; Wang Z; Sjöström M; Deng S; Wang C; Johnson NA; Gonzalez J; Li X; Metang LA; Tirado CR; Mukherji A; Wainwright G; Yu X; Yang Y; Barnes S; Hofstad M; Zhu H; Hanker A; He HH; Chen Y; Wang Z; Raj G; Arteaga C; Feng F; Wang Y; Wang T; Mu P
    bioRxiv; 2023 Oct; ():. PubMed ID: 37961351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen Receptor Signaling and Metabolic and Cellular Plasticity During Progression to Castration Resistant Prostate Cancer.
    Uo T; Sprenger CC; Plymate SR
    Front Oncol; 2020; 10():580617. PubMed ID: 33163409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.